These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31480004)

  • 1. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
    Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
    Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
    Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
    J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
    Frankenberger C; Rabe D; Bainer R; Sankarasharma D; Chada K; Krausz T; Gilad Y; Becker L; Rosner MR
    Cancer Res; 2015 Oct; 75(19):4063-73. PubMed ID: 26238785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
    Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
    Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
    Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
    Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
    Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.
    Ono H; Horinaka M; Sukeno M; Morita M; Yasuda S; Nishimoto E; Konishi E; Sakai T
    Cancer Sci; 2021 Oct; 112(10):4166-4175. PubMed ID: 34288272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
    Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
    Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
    Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
    J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
    Deng Y; Hu JC; He SH; Lou B; Ding TB; Yang JT; Mo MG; Ye DY; Zhou L; Jiang XC; Yu K; Dong JB
    Acta Pharmacol Sin; 2021 Jan; 42(1):149-159. PubMed ID: 32451413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paris saponin VII inhibits triple-negative breast cancer by targeting the MEK/ERK/STMN1 signaling axis.
    Zhang Y; Wei S; Zhang Q; Zhang Y; Sun C
    Phytomedicine; 2024 Jul; 130():155746. PubMed ID: 38763012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
    Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 18. Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
    Petruk N; Sousa S; Croset M; Polari L; Zlatev H; Selander K; Mönkkönen J; Clézardin P; Määttä J
    Eur J Pharm Sci; 2023 Nov; 190():106571. PubMed ID: 37652236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
    Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
    Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
    Lee C; Kim S; Jeong C; Cho I; Jo J; Han IH; Bae H
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.